1. Introduction
===============

Human respiratory syncytial virus (hRSV) and human metapneumovirus (hMPV) are classified within the *Paramyxoviridae* family, *Pneumovirinae* subfamily, which is divided into the *Pneumovirus* and the *Metapneumovirus* genera. Both viruses belong to the order Mononegavirales and contain a nonsegmented, negative-sense RNA with genomic organization, which is similar, but not identical \[[@B1-viruses-05-01553],[@B2-viruses-05-01553],[@B3-viruses-05-01553],[@B4-viruses-05-01553]\]. Metapneumoviruses lack the nonstructural proteins NS1 and NS2, and the gene order is different from that of pneumoviruses. hRSV is the type species of the *Pneumovirus* genus, while (based on the biological properties and genomic sequence) hMPV has been assigned to the *Metapneumovirus* genus. hRSV encodes 11 proteins (nonstructural (NS) protein1, NS2, nucleocapsid (N), phosphoprotein (P), matrix (M)1, small hydrophobic (SH), attachment (G), fusion (F), M2-1, M2-2 and polymerase (L), [Figure 1](#viruses-05-01553-f001){ref-type="fig"}), while hMPV encodes nine proteins (N, P, M1, F, M2-1, M2-2, SH, G and L, [Figure 1](#viruses-05-01553-f001){ref-type="fig"}).

![Schematic representation of human *Pneumovirus* and *Metapneumovirus*. Gene maps and encoded proteins of members of the subfamily Pneumovirinae: human respiratory syncytial virus (hRSV) and human metapneumovirus (hMPV), which belong to the genera *Pneumovirus* and *Metapneumovirus*, respectively. Genes are represented as boxes with the corresponding encoded protein.](viruses-05-01553-g001){#viruses-05-01553-f001}

hRSV was first isolated in 1956 from an infected chimpanzee \[[@B5-viruses-05-01553]\] and represents the most important cause of bronchiolitis and pneumonia in infants and young children worldwide. More than 95% of children are infected with hRSV by two years of age \[[@B1-viruses-05-01553]\]. hMPV was first identified in 2001 following its isolation from infants and children with lower respiratory tract infections (LTRI) of unknown etiology \[[@B2-viruses-05-01553]\]. Serologic evidence indicated that hMPV seropositivity is almost universal by the age of five years. The clinical manifestations of hMPV infection in young children are indistinguishable from those of hRSV infection. LRTI associated with hMPV in infants and young children is a frequent cause of hospitalization. Several studies indicate that hMPV likely accounts for 5% to 15% of LRTI hospitalizations in infants and young children and is second only to hRSV as a cause of bronchiolitis in early childhood \[[@B6-viruses-05-01553],[@B7-viruses-05-01553],[@B8-viruses-05-01553],[@B9-viruses-05-01553],[@B10-viruses-05-01553]\]. Both viruses can be transmitted mainly by large droplets from infected individuals \[[@B11-viruses-05-01553],[@B12-viruses-05-01553]\], and the incubation period could last between three and seven days for hRSV and four to six days for hMPV \[[@B13-viruses-05-01553]\]. hRSV and hMPV are present year-round, but their incidence increases in the fall, peaks in the winter and goes down in early spring \[[@B1-viruses-05-01553],[@B14-viruses-05-01553],[@B15-viruses-05-01553]\]. Host risk factors for these infections include premature birth, congenital heart disease, immunodeficiency, elderly individuals, gender and Down's syndrome, among others \[[@B16-viruses-05-01553],[@B17-viruses-05-01553],[@B18-viruses-05-01553]\]. Adults and older children are commonly reinfected without complications by these paramyxoviruses, because the natural infection does not induce lifelong immunological protection. However, it is in infants, elderly and immunosuppressed individuals that severe disease can result \[[@B19-viruses-05-01553],[@B20-viruses-05-01553],[@B21-viruses-05-01553]\]. Currently, there are no vaccines available against hRSV or hMPV. However, infected individuals can be treated with ribavirin and immunoglobulins \[[@B22-viruses-05-01553]\].

Knowledge of the critical aspects of the host immune response to these infections has been crucial to understanding the pathology associated with hRSV and hMPV infections. In that regard, dendritic cells (DC) play a pivotal role in shaping antiviral immune response in the respiratory tract, as they represent the perfect link between innate and adaptive immune response \[[@B23-viruses-05-01553],[@B24-viruses-05-01553],[@B25-viruses-05-01553]\]. Although the mechanisms underlying the activation of these cells by paramyxovirus infections still is largely unknown, substantial progress towards our understanding of the DC response to hRSV has been made, and the role of these cells in hMPV infection has also been explored.

2. Dendritic Cells in the Respiratory Tract
===========================================

Dendritic cells are professional antigen-presenting cells within the immune system. They arise from both myeloid and lymphoid progenitors within the bone marrow and are widely distributed (as immature DC) into both lymphoid and nonlymphoid tissues \[[@B26-viruses-05-01553],[@B27-viruses-05-01553],[@B28-viruses-05-01553]\]. Respiratory tract dendritic cells are present within airway epithelium, submucosa and associated lung parenchymal tissue under resting conditions \[[@B29-viruses-05-01553]\]. In the absence of inflammation, lung DC are present at an average density of several hundred cells per square millimeter in the large airways, decreasing to less than a hundred DC per square millimeter within smaller intrapulmonary airways \[[@B30-viruses-05-01553]\]. Pulmonary DC have a rapid turnover, with a half-life of ≤2 days \[[@B30-viruses-05-01553],[@B31-viruses-05-01553]\]. Their strategic localization at the site of pathogen entry makes them particularly susceptible to initial viral invasion. After detection, uptake and degradation of viruses, DC initiate immune responses via the secretion of interferon, chemokines and proinflammatory cytokines, as well as the upregulation of a variety of costimulatory molecules and receptors, a process globally known as cell maturation. After maturation, DC efficiently present antigens and initiate adaptive immune response by migrating into lymph nodes (LN) to activate the virus-specific T-cell response \[[@B32-viruses-05-01553]\].

3. Activation and Inhibition of DC Infected with hRSV and hMPV *in Vitro*
=========================================================================

3.1. DC Maturation and Cytokine Production
------------------------------------------

DC maturation is necessary for the transition from innate to adaptive immunity. In human monocyte-derived DC (moDC), hRSV and hMPV are able to induce cell maturation, indicated by an upregulation of MHC class I and class II molecules, as well as the overexpression of CD80, CD86, CD38 and CD83 \[[@B33-viruses-05-01553],[@B34-viruses-05-01553],[@B35-viruses-05-01553],[@B36-viruses-05-01553],[@B37-viruses-05-01553]\]. Cytokine production by these cells is differentially induced by hRSV and hMPV, hRSV being a more potent inducer of IL-10, TNF-α, IL-1β and IL-12p70, while hMPV induces a more robust response of type I IFN than hRSV. IFN induction is dependent of viral replication, as UV-inactivated virus failed to induce IFN in hRSV- or hMPV-infected cells \[[@B34-viruses-05-01553],[@B35-viruses-05-01553],[@B36-viruses-05-01553],[@B38-viruses-05-01553]\]. The response of human primary blood myeloid DC to hRSV has also been characterized, and it resembles that of moDC \[[@B39-viruses-05-01553]\]. hRSV also induces maturation in mouse DC. Bone marrow-derived DC (BMDC) exhibited an increased expression of CD40, CD80, CD86, MHC class I and class II and higher production of IL-6, IL-10 and IL-12p70. Consistent with reports in human cells, hRSV replication was required also for DC maturation \[[@B40-viruses-05-01553]\]. However, DC are not highly permissive to hRSV or hMPV infections, regardless of their source (PBMCs, cord-blood or primary DC), as demonstrated by the low percentage (4% to 25%) of antigen positive cells by flow cytometry analysis \[[@B33-viruses-05-01553],[@B34-viruses-05-01553],[@B35-viruses-05-01553],[@B36-viruses-05-01553],[@B37-viruses-05-01553],[@B39-viruses-05-01553],[@B41-viruses-05-01553]\]. This suggests a critical role of the virus-induced cytokines, such as type I IFN, during the maturation process, as reported in BMDC \[[@B42-viruses-05-01553]\]. Infection of plasmacytoid *dendritic cells* (pDC) by hRSV and hMPV induce differential expression of cytokines and chemokines. As in moDC, hRSV is a more potent inducer of IL-6, IL-10, GM-CSF, TNF-α, IL-1β, IL-12p70 and G-CSF than hMPV. However, both viruses induce a similar response of IFN-α release in infected pDC \[[@B33-viruses-05-01553]\].

In understanding the mechanisms of activation and maturation by hRSV, Munir*et al.* \[[@B43-viruses-05-01553]\] have reported that the NS proteins of hRSV suppress the expression of costimulatory molecules, as well as the secretion of cytokines and chemokines in human moDC in a type I IFN-dependent process. The inhibitory effect was mediated mostly by NS1 protein, but was enhanced by the combined deletion of NS2 in the same recombinant hRSV virus. More recently, Johnson*et al.* \[[@B44-viruses-05-01553]\] reported that the interaction of hRSV G protein with the DC/L-SIGN (C-type lectins commonly found in DC) inhibits maturation of primary human DC. They found that when this interaction was neutralized with specific antibodies, RSV-infected myeloid DC and pDC increased both maturation and cytokine/chemokine production \[[@B44-viruses-05-01553]\]. The role of cellular mechanisms critical for DC function has also been explored. Morris*et al.* \[[@B45-viruses-05-01553]\] investigated the role of autophagy, a cellular mechanism that involves cell degradation of unnecessary or dysfunctional cellular components \[[@B46-viruses-05-01553]\]. They found that cytokine production and the expression of surface markers (MHC class II, CD40, CD80 and CD86) was inhibited when autophagy was blocked in hRSV-infected BMDC, indicating that autophagy is a critical cellular process for DC maturation during hRSV infection \[[@B45-viruses-05-01553]\].

3.2. Activation and Inhibition of IFN Responses
-----------------------------------------------

Interferons (IFNs) are a heterogeneous family of cytokines with demonstrated antiviral, antitumor and immunomodulatory activities. The IFN family includes type I (IFN-α, -β, -ε, -κ and -ω), type II (IFN-γ) and type III (IFN-λ1, -λ2 and -λ3) IFNs \[[@B47-viruses-05-01553],[@B48-viruses-05-01553]\]. Local production of IFNs plays an important defensive role in many respiratory virus infections by limiting viral replication until virus-specific host defense mechanisms develop \[[@B49-viruses-05-01553]\]. It is known that hRSV and hMPV are able to induce and inhibit the IFN response in human and mouse DC. Moreover, they use different molecular mechanisms depending of the DC subset infected ([Table 1](#viruses-05-01553-t001){ref-type="table"}). The induction of IFN production by RNA viruses is triggered by the activation by several pattern recognition receptors that recognize different viral components. Among them, the cytosolic RNA helicases, retinoic acid-inducible gene (RIG-I) and melanoma differentiation-associated gene 5 (MDA5) play a role in recognizing short or long dsRNA, respectively \[[@B50-viruses-05-01553]\]. Other receptors include Toll-like receptors (TLR3 and TLR7) found in the endosomal compartment, which recognize dsRNA and ssRNA, respectively \[[@B51-viruses-05-01553]\].

As previously reported, both hRSV and hMPV induce a robust response of IFN-α in human pDC, and this production is dependent on viral replication \[[@B33-viruses-05-01553],[@B38-viruses-05-01553],[@B52-viruses-05-01553],[@B53-viruses-05-01553],[@B54-viruses-05-01553]\]. Using splenic mouse pDC, it has been further demonstrated that IFN production by hMPV is dependent on TLR7 expression \[[@B54-viruses-05-01553]\]. Unlike in pDC, moDC produce IFN-α mostly after infection with hMPV, not with hRSV \[[@B33-viruses-05-01553],[@B38-viruses-05-01553]\]. Using human moDC, previous results from my laboratory have demonstrated that the cytosolic helicase, MDA5, contributes to the production of type I and type III IFNs after hMPV infection. Those observations were further confirmed in an*in vivo* model of infection using MDA5^−/−^ mice \[[@B55-viruses-05-01553]\]. Activation of TLR4 has also been reported to contribute to the production of IFN-β in moDC after hMPV infection \[[@B56-viruses-05-01553]\].

Although the mechanisms underlying the differential activation of IFN response by hRSV and hMPV in moDC have not been fully elucidated, some experimental evidence indicates the involvement of several viral proteins. Munir*et al.* \[[@B43-viruses-05-01553]\] demonstrated that the hRSV NS1 and, to a lesser extent, NS2 protein suppress the expression of IFN-α/β by using recombinant RSVs bearing deletions of the NS1 and/or NS2 protein \[[@B43-viruses-05-01553]\]. In the case of hMPV, it is the expression of the protein G that is responsible for the reduced production of IFN-α/β in infected moDC \[[@B56-viruses-05-01553]\].

hRSV and hMPV infections are also known to subvert the immune responses by interfering with DC functions. The modulating mechanisms of DC immunity by these viruses have been investigated in several*in vitro* systems, including human DC. It has been shown that hRSV and hMPV inhibit the production of IFN-α in human pDC in response to TLR7 and TL9 agonists \[[@B33-viruses-05-01553],[@B52-viruses-05-01553]\] and in moDC after TLR3 activation \[[@B33-viruses-05-01553]\]. In addition, the soluble form of the G protein of hRSV and hMPV has also been reported to block the IFN response after TLR activation in moDC \[[@B56-viruses-05-01553],[@B57-viruses-05-01553]\].

Overall, these data indicate that hRSV and hMPV activate and inhibit the IFN responses in DC, most possibly through different mechanisms. This critical knowledge contributes to our understanding of the molecular mechanisms of hRSV and hMPV immunopathogenesis and may help to explain the lack of protective immunity after natural infection and the multiple reinfections by these viruses.
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###### 

Activation and inhibition of IFN responses by human respiratory syncytial virus (hRSV) and human metapneumovirus (hMPV) in dendritic cells (DC). pDC, plasmacytoid *dendritic cells*; moDC, monocyte-derived DC.

  **Virus**          **Effect**                        **DC Subset**   **References**
  ------------------ --------------------------------- --------------- -----------------------------------------------------------------------------------------------------
  hRSV               Induce IFN-α                      pDC             \[[@B33-viruses-05-01553],[@B38-viruses-05-01553],[@B52-viruses-05-01553],[@B53-viruses-05-01553]\]
  hRSV               Blocks TLR7 and TLR9 activation   pDC             \[[@B33-viruses-05-01553],[@B52-viruses-05-01553]\]
  hRSV               Blocks TLR3 activation            moDC            \[[@B33-viruses-05-01553]\]
  hRSV NS1 and NS2   Suppress IFN-α/β production       moDC            \[[@B43-viruses-05-01553]\]
  hRSV soluble G     Blocks TLR3 and TLR4 activation   moDC            \[[@B57-viruses-05-01553]\]
  hMPV               Induce IFN-α                      pDC             \[[@B33-viruses-05-01553],[@B54-viruses-05-01553]\]
  hMPV               Induce IFN-α, β, λ                moDC            \[[@B33-viruses-05-01553],[@B55-viruses-05-01553]\]
  hMPV               Activates MDA5                    moDC            \[[@B55-viruses-05-01553]\]
  hMPV               Activates TLR4                    moDC            \[[@B56-viruses-05-01553]\]
  hMPV               Activates TLR7                    pDC             \[[@B54-viruses-05-01553]\]
  hMPV               Blocks TLR7 activation            pDC             \[[@B33-viruses-05-01553]\]
  hMPV               Blocks TLR3 activation            moDC            \[[@B33-viruses-05-01553]\]
  hMPV G             Suppresses IFN-α/β production     moDC            \[[@B56-viruses-05-01553]\]

3.3. Regulation of T-Cell Responses
-----------------------------------

Another aspect of the biology of hRSV and hMPV is that they reinfect throughout life, suggesting incomplete or transient immunity \[[@B19-viruses-05-01553],[@B58-viruses-05-01553],[@B59-viruses-05-01553],[@B60-viruses-05-01553]\]. Several pieces of evidence indicate that hRSV and hMPV interact with dendritic cells and that the primary T-cell response to these viruses is altered significantly by this interaction. Human DC infected with hRSV have shown a severely impaired capacity to stimulate naive CD4^+^ T-cell proliferation \[[@B33-viruses-05-01553],[@B36-viruses-05-01553],[@B61-viruses-05-01553]\]. The possible mechanisms of this inhibition has been attributed to soluble factors in the supernatant of hRSV-infected dendritic cells \[[@B36-viruses-05-01553]\], as well as to direct contact with RSV-infected cells to inhibit proliferation of T-cells \[[@B52-viruses-05-01553],[@B61-viruses-05-01553]\]. In fact, *Gonzalez et al.* \[[@B40-viruses-05-01553]\] demonstrated, in bone marrow-derived DC (BMDC), that immunological synapse assembly between hRSV-infected DC and T-cells was impaired, supporting the notion that contact is necessary for the inhibition of T-cell activation by hRSV infection \[[@B40-viruses-05-01553]\]. Inhibition of T-cell proliferation by hMPV-infected DC, however, has also been attributed to soluble factors secreted by hMPV-infected DC, but not by interference with DC-T-cell immunological synapse formation \[[@B62-viruses-05-01553]\]. Others have not observed this inhibitory effect using hRSV-infected cord blood-derived DC or moDC cultured with naive T-cells and superantigens \[[@B37-viruses-05-01553],[@B63-viruses-05-01553]\]. Whether this discrepancy in the activation of the T-cells by hRSV-infected cells is related to the different experimental conditions remains to be determined. Further characterization of the interaction between T-cells and hRSV- and hMPV-infected DC is warranted.

4. Response of Human Dendritic Cells to hRSV Infection *in Vivo*
================================================================

Current characterization of human lung DC populations includes three types of DC: two myeloid DC (mDC) in the lung parenchyma (mDC1 (BDCA-1^+^/HLA-DR^+^) and mDC2 (CD11c^+^/BDCA-3^+^)) and one pDC subset (CD11c^−^/BDCA-2^+^/CD123^+^/CD14^−^/HLA-DR^+^) \[[@B64-viruses-05-01553],[@B65-viruses-05-01553],[@B66-viruses-05-01553]\]. Additional reports have confirmed the presence of these lung DC subsets in human bronchoalveolar lavage samples \[[@B67-viruses-05-01553],[@B68-viruses-05-01553]\]. However, further characterization of human lung DC populations, under the steady state and in response to stimulus, is needed in order to define the composition of human DC in the lung.

There have been a limited number of studies focused on the DC response to hRSV or hMPV infections in humans. In fact, the response of pulmonary DC in hMPV-infected individuals has not yet been reported. However, despite the human sample limitations, analyses of nasal washes from young children with acute hRSV infection have revealed that hRSV attracts both mDC and pDC to the site of viral entry. The number of pDC, and, to a lesser extent, that of mDC, positively correlates with the viral load in the infected individuals \[[@B69-viruses-05-01553]\]. However, hRSV recruits DC to a lesser extent relative to other relevant respiratory viruses, such as influenza virus \[[@B70-viruses-05-01553]\]. On the other hand, the numbers of mDC and pDC decreased in peripheral blood, suggesting that the increase of mDC and pDC in nasal mucosa results from their migration from the blood \[[@B69-viruses-05-01553],[@B70-viruses-05-01553]\]. In line with those data, Silver E.*et al.* \[[@B71-viruses-05-01553]\] has found that the lower levels of pDC in peripheral blood have been associated with asthma after severe hRSV bronchiolitis \[[@B71-viruses-05-01553]\]. Overall, these data indicate a relevant role of DC in hRSV infection in humans. However, the better understanding of the response of DC to hRSV or hMPV has been revealed from*in vitro* experiments using human and mouse cells and from experimental animal models, specifically, the mouse model.

5. Response of Pulmonary DC in Experimental Mouse Models after hRSV and hMPV Infection
======================================================================================

Because the study of the human DC at multiple stages of respiratory viral infections is technically and ethically difficult, the experimental mouse model has provided an excellent opportunity to investigate the response of DC*in vivo*. To date, there have been at least three major subsets of murine lung DC described. These include plasmacytoid DC (pDC), the myeloid DC (also known as conventional DC (cDC)) and the interferon-producing killer dendritic cells (IKDC) ([Figure 2](#viruses-05-01553-f002){ref-type="fig"}). All three DC populations have been reported to participate in the innate and adaptive immune response to hRSV and hMPV infections, indicating their critical role in the antiviral immunity to these viruses.

![Mouse lung DC activated during hRSV and hMPV infection.](viruses-05-01553-g002){#viruses-05-01553-f002}

pDC are identified by the expression of CD11c^int^/B220^+^/Gr-1^+^/Siglec-H^+^/mPDCA1^+^. They are best known for secreting large amounts of type I interferons (IFN) in response to viral infections \[[@B72-viruses-05-01553]\]. Type I IFN confer resistance to viral infections and promote apoptosis of virally infected cells \[[@B73-viruses-05-01553]\]. Also, type I IFN promote myeloid DC, B-cells, T-cells and natural killer (NK) cell functions \[[@B74-viruses-05-01553],[@B75-viruses-05-01553]\]. Therefore, pDC regulate both innate and adaptive immune response in viral infections. pDC can also present endogenous viral antigens in their activated state to CD4^+^ T-cells, but they are less efficient antigen-presenting cells, as compared to cDC \[[@B76-viruses-05-01553]\]. Additionally, pDC are able to produce a variety of cytokines and chemokines that are important for the activation and trafficking of CD4^+^ and CD8^+^ T-cells to the site of infection \[[@B77-viruses-05-01553],[@B78-viruses-05-01553]\].

cDC are identified as major histocompatibility complex class II (MHC-II)^hi^/CD11c^hi^. They are considered the main antigen-presenting cells of the immune system \[[@B26-viruses-05-01553],[@B79-viruses-05-01553]\]. In mice, lung cDC comprise two major cDC subpopulations based on the expression of the integrin marker, CD103, and myeloid marker, CD11b, to give place to MHC-II^hi^/CD11c^hi^/CD11b^−^/CD103^+^ in the intraepithelial network and the parenchymal MHC-II^hi^/CD11c^hi^/CD11b^+^/CD103^−^ DC \[[@B79-viruses-05-01553]\]. These two cDC subsets differ in their relative abilities to prime CD4^+^ and CD8^+^ T-cells \[[@B80-viruses-05-01553]\], produce proinflammatory cytokines and generate Foxp3-mediated regulatory function of naive T-cells \[[@B81-viruses-05-01553],[@B82-viruses-05-01553]\]. CD103 (α~E~) is the α-chain of the α~E~β~7~ integrin that mediates human and mouse T lymphocyte adhesion to epithelial cells through its binding to E-cadherin, which is selectively expressed on the basolateral side of epithelial cells \[[@B83-viruses-05-01553]\]. The MHC-II^hi^/CD11c^hi^/CD11b^−^/CD103^+^ DC are also known as migratory DC. CD103^+^ DC can migrate to the draining lymph nodes (LN), produce IL-12 and are specialized in cross‑presentation \[[@B80-viruses-05-01553],[@B82-viruses-05-01553]\]. MHC-II^hi^/CD11c^hi^/CD11b^+^/CD103^−^ DC are more efficient at presenting antigens on MHC II \[[@B84-viruses-05-01553]\].

IKDC are characterized by the expression of CD11c^int^/Gr-1^+^/DX5^+^ or NK1.1^+^. They are present in the lung and express cell surface markers of DC, as well as NK cell markers \[[@B85-viruses-05-01553],[@B86-viruses-05-01553]\]. IKDC could be considered as NK-like DC or DC-like NK cells, playing a major role as a distinct population of innate effectors against viral pathogens \[[@B85-viruses-05-01553],[@B87-viruses-05-01553],[@B88-viruses-05-01553]\]. However, their classification \[[@B85-viruses-05-01553],[@B86-viruses-05-01553],[@B88-viruses-05-01553],[@B89-viruses-05-01553],[@B90-viruses-05-01553]\], origin \[[@B91-viruses-05-01553]\] and physiological roles \[[@B85-viruses-05-01553],[@B87-viruses-05-01553],[@B92-viruses-05-01553],[@B93-viruses-05-01553]\] remain controversial.

More recently, the TNF-α/inducible nitric oxide synthase (iNOS)-producing DC (tipDC) have been identified and found to control viral infections in the lung \[[@B94-viruses-05-01553]\]. However, their role in hRSV or hMPV has not yet been described. TipDC, also known as inflammatory DC or activated macrophages, contribute to the control of the antimicrobial defense and are responsible for severe tissue damage in several models of infection \[[@B94-viruses-05-01553],[@B95-viruses-05-01553],[@B96-viruses-05-01553],[@B97-viruses-05-01553]\]. However, based on the overlapping phenotypes of myeloid cells, further characterization of lung tipDC is needed in order to eliminate the possibility that they represent myeloid cells in a transient maturation stage, in response to infection.

5.1. Lung DC Trafficking
------------------------

Several studies have reported the trafficking and function of respiratory DC in response to hRSV or hMPV infection. Experimental evidence indicates that hRSV induces the recruitment of DC into the lungs and LN of BALB/c \[[@B98-viruses-05-01553],[@B99-viruses-05-01553],[@B100-viruses-05-01553]\] and C57BL/6 \[[@B101-viruses-05-01553]\] mice. In previous studies, I have observed that IKDC is the smallest DC subset recruited to the airways upon hRSV infection (two-fold) \[[@B98-viruses-05-01553]\], followed by pDC (four-fold) and is the cDC the predominant DC population recruited to the lung after hRSV infection (20-fold) \[[@B98-viruses-05-01553]\]. Some differences in the kinetics of pDC and IKDC into the lung of hMPV‑infected mice have been observed when compared to hRSV, as the recruitment of pDC and IKDC peaked by day eight after hMPV infection*versus* day three in hRSV-infected mice \[[@B98-viruses-05-01553]\]. On the other hand, a similar trafficking pattern of cDC has been observed after hMPV infection when compared to hRSV \[[@B98-viruses-05-01553]\], including a sustained recruitment of this cell population for about 18--21 days beyond the acute phase of infection \[[@B98-viruses-05-01553],[@B99-viruses-05-01553]\]. It has also been found that CD103^+^ cDC are substantially decreased after hRSV infection \[[@B98-viruses-05-01553],[@B101-viruses-05-01553]\], and the same effect has been observed in the lungs of hMPV-infected mice in which CD103^+^ cDC decreased even after three weeks of infection and returned to basal levels by week eight \[[@B98-viruses-05-01553]\]. By contrast, after either hRSV or hMPV infection, CD11b^hi^ cDC increased about four-fold in the lung of infected mice \[[@B98-viruses-05-01553],[@B101-viruses-05-01553]\]. Furthermore, hRSV infection stimulates the mobilization of both populations of cDC, as the numbers of CD103^+^ and CD11b^hi^ are increased in the lung-draining mediastinal LN \[[@B101-viruses-05-01553]\].

5.2. Lung DC Activation
-----------------------

Upon viral challenge, lung cDC are activated and acquire a mature phenotype \[[@B23-viruses-05-01553],[@B26-viruses-05-01553],[@B28-viruses-05-01553],[@B102-viruses-05-01553]\]. In that regard, previous experimental observations indicate that hRSV or hMPV induce the overexpression of surface molecules, including CD40, CD80, CD86, PD-L1, OX-40L and MHC-II, in pulmonary cDC as early as day one after infection and remained activated until three weeks after infection \[[@B98-viruses-05-01553],[@B101-viruses-05-01553],[@B103-viruses-05-01553]\]. Moreover, the profile of cytokines produced by pulmonary pDC and cDC, infected with hRSV or hMPV, differ substantially. cDC produce IL-10, IL-1α, IL-6, CXCL1 and CCL11, while pulmonary pDC do not. However, both lung cDC and pDC produce IFN-α after hMPV infection*ex vivo*, while infection with hRSV did not stimulate the release of the antiviral cytokine \[[@B98-viruses-05-01553]\]. hRSV also induces maturation of lung pDC, as indicated by the overexpression of CD80, CD86 and MHC class II molecules \[[@B104-viruses-05-01553]\].

5.3. Lung pDC Function in hRSV Infection
----------------------------------------

It has been demonstrated that the balance between the numbers of pDC and cDC in the lung is important for the regulation of the immune response against hRSV. Smit*et al.* \[[@B105-viruses-05-01553]\] demonstrated that when both pDC and cDC populations were expanded in hRSV-infected mice, that resulted in a decreased Th2 cell response, but an increased Th1 response and lower immunopathology. However, by depleting pDC and expanding cDC, the T-cell response was skewed towards Th2, resulting in an exacerbated inflammatory response.

The specific role of pulmonary pDC in hRSV infection has also been explored by several other groups \[[@B100-viruses-05-01553],[@B104-viruses-05-01553],[@B106-viruses-05-01553]\]. To this end, pDC have also been depleted with the monoclonal antibody (mAb), 120G8, that recognizes the murine surface antigen, CD317 (BST-2; mPDCA1), in several mouse strains \[[@B107-viruses-05-01553]\]. Some studies have reported that the inflammatory response and the airway resistance was substantially exacerbated, and the lung viral titer was increased \[[@B100-viruses-05-01553],[@B104-viruses-05-01553]\], suggesting that pDC play a protective role during hRSV infection. However, it is important to consider that, despite BST-2 antigen being expressed predominantly on pDC in naive mice, it is known that after viral infection or stimulation with type I or type II IFN, BST-2 is induced on most cell types \[[@B108-viruses-05-01553]\]. Therefore, this fact should be taken into consideration for the interpretation of these studies. On the hand, it seems that pDC do not contribute significantly to the production of type I IFN*in vivo* in hRSV infection, as the levels of IFN‑α and IFN-β remained unchanged in hRSV-infected mice after successful depletion of pDC \[[@B106-viruses-05-01553]\]. In fact, it has been reported that alveolar macrophages are the primary IFN-α producer in lung infections by RNA viruses \[[@B109-viruses-05-01553]\]. In support to that, Pribul*et al.* \[[@B110-viruses-05-01553]\] has demonstrated that alveolar macrophages significantly contribute to the production of IFN-α in hRSV infection. As for the role of DC subsets in hMPV infection, there are no reports exploring the contribution of these cells in the hMPV-induced immune response. Therefore, future experiments aimed to determine the role of DC subpopulations in hMPV-infected mice are needed to understand the contribution of these cells in hMPV-induced immune response.

5.4. Impairment of Mouse Lung DC Response in hRSV and hMPV
----------------------------------------------------------

Infection by hRSV and hMPV is characterized by short-lasting virus specific immunity and, often, long-term airway morbidity. Previous studies have revealed that hRSV or hMPV impair the capacity of human DC to present antigens to T-cells*in vitro* \[[@B33-viruses-05-01553],[@B101-viruses-05-01553],[@B111-viruses-05-01553]\]. That detrimental effect has also been observed in experiments*in vivo* using the mouse model \[[@B98-viruses-05-01553]\]. In that system, I have previously observed that, when compared with cDC from mock-infected mice, lung cDC from mice infected with hRSV or hMPV have an impaired capacity to present antigens to CD4^+^ T-cells that lasted beyond the acute phase of infection, suggesting that acute pneumovirus and metapneumovirus infections can alter the long-term immune function of pulmonary DC. Moreover, that inhibitory effect seems to be selective for lung cells, since that inhibitory effect was not observed when spleen cDC from the same infected mice were used \[[@B98-viruses-05-01553]\]. The mechanisms by which hRSV and hMPV impair cDC function are largely unknown. However, one of the surface molecules that was upregulated after viral infection in lung cDC was programmed death-1 ligand (PD-L1) \[[@B98-viruses-05-01553]\], which is known to inhibit some T-cell functions, including T-cell proliferation \[[@B112-viruses-05-01553],[@B113-viruses-05-01553],[@B114-viruses-05-01553]\], suggesting that this molecule may play a role in the impaired capacity of cDC to present antigens to T-cells after hRSV and hMPV infection.

The production of type I IFN and other cytokines by lung DC is also altered by hRSV and hMPV infection*in vivo* \[[@B98-viruses-05-01553]\]. I have previously observed that lung pDC isolated from infected mice produced significantly lower levels of IFN-α, IL-6, TNF-α, CCL3, CCL4 and CCL5 in response to CpG ODN \[[@B98-viruses-05-01553]\], indicating that both viruses are able to interfere with the capacity of pulmonary pDC to mount an antiviral response in response to a secondary stimulus. Age is also a factor that negatively impacts DC response in the lung. The recruitment of DC after hRSV infection can be impaired by the age of the infected individuals, as shown by Zhao*et al.* in aged mice (6--22 months-old) where the ability of lung DC to migrate to LN was compromised in hRSV-infected aged mice, with a decline in migration occurring as early as six months of age \[[@B115-viruses-05-01553]\].

5.5. Contribution Lung DC in Vaccine Development
------------------------------------------------

Data*in vivo* using the C57BL/6 mouse model of hRSV infection have indicated that after hRSV intranasal challenge to formalin-inactivated RSV (FI-RSV)-immunized mice, the numbers of CD11b^+^ and CD103^+^ cDC recruited into the lung are increased \[[@B116-viruses-05-01553]\]. Considering that differences between these DC populations in priming the T-cell responses exist \[[@B80-viruses-05-01553]\] and that the balance between the numbers of DC subsets influences the CD4^+^ Th1/Th2 responses in the lung \[[@B105-viruses-05-01553]\], the development of hRSV and hMPV vaccines should consider the characterization of the lung DC subsets response and their contribution to prime an immune response against these viral infections, which will contribute toward the better design of an effective vaccine against these respiratory viral infections.

6. Conclusions
==============

Lung DC participate in the innate and adaptive immune response to hRSV and hMPV infections, indicating their critical role in the antiviral immunity to these paramyxoviruses. hRSV and hMPV can induce similar DC responses, as DC can be activated by both hRSV and hMPV infections*in vivo*. In addition, both viruses can induce the maturation and trafficking of the different DC populations from lung to LN. Moreover, they interfere with the T-cell response, as the antigen-presenting capacity of pulmonary DC to T-cells is impaired after hRSV or hMPV infection, which may contribute to the lack of protection and multiple reinfections by these viruses. On the other hand, hRSV and hMPV differentially induce the production of type I IFN in lung DC, as hMPV is a more potent inducer of the antiviral cytokine.

Although many aspects of the immune mechanisms involving DC in hRSV infection have not been elucidated, considerable progress has been made with respect to our understanding of the role of pulmonary DC in hRSV infection. However, less is known regarding the interaction of hMPV with the lung DC, and in general, the mechanisms that regulate the host immune response to hMPV infection remain largely unknown. Additional studies are necessary to better understand the mechanisms that regulate the DC response in hRSV and hMPV infections.
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